Correction: Clinical efficacy and predictive factors of photodynamic therapy combined with recombinant mussel mucin repair dressing in treating post-inflammatory hyperpigmentation - Scorecard - MDSpire

Correction: Clinical efficacy and predictive factors of photodynamic therapy combined with recombinant mussel mucin repair dressing in treating post-inflammatory hyperpigmentation

  • By

  • Jianjun Nie

  • Zengmiao Hou

  • Peimei Zhou

  • Ya Zhang

  • Yonghong Lu

  • June 24, 2026

  • 0 min

Share

Clinical Scorecard: Erratum: Evaluating the Clinical Effectiveness and Predictive Variables of Combining Photodynamic Therapy with Recombinant Mussel Mucin Dressing for Post-Inflammatory Hyperpigmentation Treatment

At a Glance

CategoryDetail
ConditionPost-Inflammatory Hyperpigmentation
Key MechanismsPhotodynamic therapy combined with recombinant mussel mucin dressing
Target PopulationPatients with post-inflammatory hyperpigmentation
Care SettingClinical dermatology

Key Highlights

  • Correction of figures for clarity and completeness
  • Figures updated to include names of chemical compounds
  • No impact on scientific results or conclusions

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Patients experiencing post-inflammatory hyperpigmentation

          Combination therapy with photodynamic therapy and mucin dressing

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Clinical efficacy and predictive factors of photodynamic therapy combined with recombinant mussel mucin repair dressing in treating post-inflammatory hyperpigmentation

            • by Jianjun Nie, Zengmiao Hou, Peimei Zhou, Ya Zhang, Yonghong Lu

            • June 24, 2026

            Related Content

            Letter to the Editor Regarding “Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis”

            Optimized nursing strategies for skin graft outcomes: a narrative review of current evidence

            Case Report: FOLFOX-induced vulvar mucositis: a rare side effect of 5-FU